Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 7/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13241039 | 0.84 | P2RY14 (0.43) | MAP3K5PTGDR2CAPN1MCL1KDM4E | |
| SCHEMBL3671935 | 0.82 | MAP3K5 (0.39) | MAP3K5PTGDR2PIK3C3CAPN1MCL1 | |
| SCHEMBL13241037 | 0.78 | PTGDR2 (0.40) | MAP3K5PTGDR2PIK3C3 | |
| SCHEMBL3613975 | 0.78 | IKBKB (0.42) | PTGDR2 | |
| SCHEMBL13981531 | 0.77 | CA12 (0.48) | MAP3K5PTGDR2PIK3C3 | |
| Trifluoroacetic Acid SCHEMBL2989883 | 0.76 | MAP3K5 (0.64) | MAP3K5CAPN1 | |
| SCHEMBL3417470 | 0.75 | IKBKB (0.43) | PTGDR2 | |
| SCHEMBL2980723 | 0.74 | MAP3K5 (0.52) | MAP3K5PTGDR2CAPN1MCL1 | |
| SCHEMBL2987892 | 0.74 | IKBKB (0.38) | MAP3K5PTGDR2PIK3C3 | |
| SCHEMBL2987895 | 0.73 | IKBKB (0.45) | MAP3K5PTGDR2PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | MAP3K5 7/4885PTGDR2 565/4885PIK3C3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.